News
[Announcement] Official Letter Confirming VAIM’s Patent Ownership and Technological Independence
Author
Ju**************
Date
2025-07-04 16:20
Views
149
Official Letter Confirming VAIM’s Patent Ownership and Technological Independence
Dear Respected Partners and Clients,
We value our continued collaboration based on mutual trust, and hereby wish to formally convey our
position regarding the independence of our technology and the status of our patent portfolio as follows:
VAIM currently holds valid domestic and international patents related to the exclusive manufacturing of its
commercialized products, "Juvelook" and "Juvelook Volume." These technologies are based on our
proprietary capabilities, developed through independent research and development efforts.
We take our legal and ethical responsibility for the protection of intellectual property rights very seriously.
All of our technologies and products have been lawfully developed through rigorous legal and technical review.
Assessments conducted by both internal and external experts also clearly confirm that our
technologies do not infringe upon the patents of any third party.
Accordingly, we hereby officially state that the recent concerns raised regarding patent matters and
the potential impact on our production, domestic and international sales, or exports are entirely unfounded.
We are currently preparing all necessary legal actions in response.
We remain firmly committed to upholding responsible corporate practices grounded in independent
technological innovation and the lawful development of our patent portfolio, while continuing to place
the highest value on the trust and confidence of our customers and the market.
In the interest of clarity and accuracy, translations in each relevant national language are enclosed as PDF
attachments at the end of this official letter for your reference.
We appreciate your continued trust and support.
VAIM Co., Ltd.
Introduction of VAIM
Founded in 2014, VAIM is a global medical aesthetics company that develops human tissue regeneration products and improved pharmaceuticals by utilizing its accumulated technology and know-how in biocompatible and biodegradable polymers. It has developed and patented a PDLLA-based manufacturing technology that reduces the risk of nodule formation compared to other ingredient structures, and in 2019, its subsidiary, VAIM, entered the skin booster market with JUVELOOK, which utilizes this technology. JUVELOOK is a collagen booster that induces the production of ECM (collagen, elastin) to provide direct remodeling effects on the skin such as elasticity and wrinkle improvement, and is divided into JUVELOOK and LENISNA depending on the purpose. After quickly proving its safety and effectiveness since its launch, VAIM currently has product export contracts with 72 countries.
Dear Respected Partners and Clients,
We value our continued collaboration based on mutual trust, and hereby wish to formally convey our
position regarding the independence of our technology and the status of our patent portfolio as follows:
VAIM currently holds valid domestic and international patents related to the exclusive manufacturing of its
commercialized products, "Juvelook" and "Juvelook Volume." These technologies are based on our
proprietary capabilities, developed through independent research and development efforts.
We take our legal and ethical responsibility for the protection of intellectual property rights very seriously.
All of our technologies and products have been lawfully developed through rigorous legal and technical review.
Assessments conducted by both internal and external experts also clearly confirm that our
technologies do not infringe upon the patents of any third party.
Accordingly, we hereby officially state that the recent concerns raised regarding patent matters and
the potential impact on our production, domestic and international sales, or exports are entirely unfounded.
We are currently preparing all necessary legal actions in response.
We remain firmly committed to upholding responsible corporate practices grounded in independent
technological innovation and the lawful development of our patent portfolio, while continuing to place
the highest value on the trust and confidence of our customers and the market.
In the interest of clarity and accuracy, translations in each relevant national language are enclosed as PDF
attachments at the end of this official letter for your reference.
We appreciate your continued trust and support.
VAIM Co., Ltd.
Introduction of VAIM
Founded in 2014, VAIM is a global medical aesthetics company that develops human tissue regeneration products and improved pharmaceuticals by utilizing its accumulated technology and know-how in biocompatible and biodegradable polymers. It has developed and patented a PDLLA-based manufacturing technology that reduces the risk of nodule formation compared to other ingredient structures, and in 2019, its subsidiary, VAIM, entered the skin booster market with JUVELOOK, which utilizes this technology. JUVELOOK is a collagen booster that induces the production of ECM (collagen, elastin) to provide direct remodeling effects on the skin such as elasticity and wrinkle improvement, and is divided into JUVELOOK and LENISNA depending on the purpose. After quickly proving its safety and effectiveness since its launch, VAIM currently has product export contracts with 72 countries.
Connect
